BACKGROUND: No single clinical or biologic marker reliably predicts clinical outcomes in acute lung injury (ALI)/ARDS. We hypothesized that a combination of biologic and clinical markers would be superior to either biomarkers or clinical factors alone in predicting ALI/ARDS mortality and would provide insight into the pathogenesis of clinical ALI/ARDS. METHODS: Eight biologic markers that reflect endothelial and epithelial injury, inflammation, and coagulation (von Willebrand factor antigen, surfactant protein D [SP-D]), tumor necrosis factor receptor-1, interleukin [IL]-6, IL-8, intercellular adhesion molecule-1, protein C, plasminogen activator inhibitor-1) were measured in baseline plasma from 549 patients in the ARDSNet trial of low vs high positive end-expiratory pressure. Mortality was modeled with multivariable logistic regression. Predictors were selected using backward elimination. Comparisons between candidate models were based on the receiver operating characteristics (ROC) and tests of integrated discrimination improvement. RESULTS:Clinical predictors (Acute Physiology And Chronic Health Evaluation III [APACHE III], organ failures, age, underlying cause, alveolar-arterial oxygen gradient, plateau pressure) predicted mortality with an area under the ROC curve (AUC) of 0.82; a combination of eight biomarkers and the clinical predictors had an AUC of 0.85. The best performing biomarkers were the neutrophil chemotactic factor, IL-8, and SP-D, a product of alveolar type 2 cells, supporting the concept that acute inflammation and alveolar epithelial injury are important pathogenetic pathways in human ALI/ARDS. CONCLUSIONS: A combination of biomarkers and clinical predictors is superior to clinical predictors or biomarkers alone for predicting mortality in ALI/ARDS and may be useful for stratifying patients in clinical trials. From a pathogenesis perspective, the degree of acute inflammation and alveolar epithelial injury are highly associated with the outcome of human ALI/ARDS.
RCT Entities:
BACKGROUND: No single clinical or biologic marker reliably predicts clinical outcomes in acute lung injury (ALI)/ARDS. We hypothesized that a combination of biologic and clinical markers would be superior to either biomarkers or clinical factors alone in predicting ALI/ARDS mortality and would provide insight into the pathogenesis of clinical ALI/ARDS. METHODS: Eight biologic markers that reflect endothelial and epithelial injury, inflammation, and coagulation (von Willebrand factor antigen, surfactant protein D [SP-D]), tumornecrosis factor receptor-1, interleukin [IL]-6, IL-8, intercellular adhesion molecule-1, protein C, plasminogen activator inhibitor-1) were measured in baseline plasma from 549 patients in the ARDSNet trial of low vs high positive end-expiratory pressure. Mortality was modeled with multivariable logistic regression. Predictors were selected using backward elimination. Comparisons between candidate models were based on the receiver operating characteristics (ROC) and tests of integrated discrimination improvement. RESULTS: Clinical predictors (Acute Physiology And Chronic Health Evaluation III [APACHE III], organ failures, age, underlying cause, alveolar-arterial oxygen gradient, plateau pressure) predicted mortality with an area under the ROC curve (AUC) of 0.82; a combination of eight biomarkers and the clinical predictors had an AUC of 0.85. The best performing biomarkers were the neutrophil chemotactic factor, IL-8, and SP-D, a product of alveolar type 2 cells, supporting the concept that acute inflammation and alveolar epithelial injury are important pathogenetic pathways in human ALI/ARDS. CONCLUSIONS: A combination of biomarkers and clinical predictors is superior to clinical predictors or biomarkers alone for predicting mortality in ALI/ARDS and may be useful for stratifying patients in clinical trials. From a pathogenesis perspective, the degree of acute inflammation and alveolar epithelial injury are highly associated with the outcome of human ALI/ARDS.
Authors: Polly E Parsons; Michael A Matthay; Lorraine B Ware; Mark D Eisner Journal: Am J Physiol Lung Cell Mol Physiol Date: 2004-10-29 Impact factor: 5.464
Authors: Robert E Gerszten; Frank Accurso; Gordon R Bernard; Richard M Caprioli; Eric W Klee; George G Klee; Iftikhar Kullo; Theresa A Laguna; Frederick P Roth; Marc Sabatine; Pothur Srinivas; Thomas J Wang; Lorraine B Ware Journal: Am J Physiol Lung Cell Mol Physiol Date: 2008-05-02 Impact factor: 5.464
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason Journal: N Engl J Med Date: 2004-04-01 Impact factor: 91.245
Authors: Carolyn S Calfee; Mark D Eisner; Polly E Parsons; B Taylor Thompson; Edward R Conner; Michael A Matthay; Lorraine B Ware Journal: Intensive Care Med Date: 2008-08-01 Impact factor: 17.440
Authors: S C Donnelly; R M Strieter; S L Kunkel; A Walz; C R Robertson; D C Carter; I S Grant; A J Pollok; C Haslett Journal: Lancet Date: 1993-03-13 Impact factor: 79.321
Authors: Roy G Brower; Paul N Lanken; Neil MacIntyre; Michael A Matthay; Alan Morris; Marek Ancukiewicz; David Schoenfeld; B Taylor Thompson Journal: N Engl J Med Date: 2004-07-22 Impact factor: 91.245
Authors: A Fernandez-Bustamante; R B Easley; M Fuld; D Mulreany; D Chon; J F Lewis; B A Simon Journal: Respir Physiol Neurobiol Date: 2012-06-21 Impact factor: 1.931
Authors: Xiaoguang Sun; Patrick A Singleton; Eleftheria Letsiou; Jing Zhao; Patrick Belvitch; Saad Sammani; Eddie T Chiang; Liliana Moreno-Vinasco; Michael S Wade; Tong Zhou; Bin Liu; Ioannis Parastatidis; Leonor Thomson; Harry Ischiropoulos; Viswanathan Natarajan; Jeffrey R Jacobson; Roberto F Machado; Steven M Dudek; Joe G N Garcia Journal: Am J Respir Cell Mol Biol Date: 2012-07-05 Impact factor: 6.914
Authors: James H Finigan; Rangnath Mishra; Vihas T Vasu; Lori J Silveira; David E Nethery; Theodore J Standiford; Ellen L Burnham; Marc Moss; Jeffrey A Kern Journal: Eur Respir J Date: 2012-05-17 Impact factor: 16.671
Authors: Carolyn S Calfee; Lorraine B Ware; David V Glidden; Mark D Eisner; Polly E Parsons; B Taylor Thompson; Michael A Matthay Journal: Crit Care Med Date: 2011-04 Impact factor: 7.598
Authors: Ashish Agrawal; Michael A Matthay; Kirsten N Kangelaris; John Stein; Jeffrey C Chu; Brandon M Imp; Alfredo Cortez; Jason Abbott; Kathleen D Liu; Carolyn S Calfee Journal: Am J Respir Crit Care Med Date: 2013-04-01 Impact factor: 21.405
Authors: Jeffrey E Gotts; Lauren Chun; Jason Abbott; Xiaohui Fang; Naoki Takasaka; Stephen L Nishimura; Matthew L Springer; Suzaynn F Schick; Carolyn S Calfee; Michael A Matthay Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-03-15 Impact factor: 5.464
Authors: Ana Fernandez-Bustamante; Jelena Klawitter; John E Repine; Amanda Agazio; Allison J Janocha; Chirag Shah; Marc Moss; Ivor S Douglas; Zung Vu Tran; Serpil C Erzurum; Uwe Christians; Tamas Seres Journal: Anesthesiology Date: 2014-09 Impact factor: 7.892